IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 78 
Small font sizeDefault font sizeIncrease font size
Navigate Here
  Search
 
  Next article
  Previous article 
  Table of Contents
  
Resource Links
   Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
   Article in PDF (133 KB)
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)

 
In This Article
   References

 Article Access Statistics
    Viewed1188    
    Printed59    
    Emailed1    
    PDF Downloaded261    
    Comments [Add]    
    Cited by others 2    

Recommend this journal

 


 
LETTER TO EDITOR
Year : 2010  |  Volume : 42  |  Issue : 2  |  Page : 117
 

Pharmacovigilance in vaccines


Department of Pharmacovigilance and Drug Safety, MakroCare, Hyderabad - 500 033, Andhra Pradesh, India

Date of Web Publication23-Jun-2010

Correspondence Address:
Salil Budhiraja
Department of Pharmacovigilance and Drug Safety, MakroCare, Hyderabad - 500 033, Andhra Pradesh
India
Login to access the Email id


DOI: 10.4103/0253-7613.64488

PMID: 20711383

Get Permissions



How to cite this article:
Budhiraja S, Akinapelli R. Pharmacovigilance in vaccines. Indian J Pharmacol 2010;42:117

How to cite this URL:
Budhiraja S, Akinapelli R. Pharmacovigilance in vaccines. Indian J Pharmacol [serial online] 2010 [cited 2014 Jul 28];42:117. Available from: http://www.ijp-online.com/text.asp?2010/42/2/117/64488


Sir,

Vaccines are among the safest tools of modern medicine that help in protecting against disease by inducing immunity. In all countries, routine immunization represents a fundamental service of the public health system, offering one of the most cost-effective methods of reducing morbidity and mortality among children less than five. A lack of complete vaccine coverage increases the risk of disease for the entire population. Pharmacovigilance is the science related to the safety of drugs and it helps prevent harmful effects of the drugs in population. It originated with thalidomide tragedy that caused 10000 birth defects in children. Regulatory systems were established soon to bring an improvement in post-marketing surveillance for the safer medicines. [1]

Since the majority of vaccines are administered to a vulnerable (children) as well as healthy population, a strict safety supervision of vaccines is essential. Safety issues in vaccines may lead to rumors and undermine a general confidence in vaccination and, ultimately, have dramatic consequences on immunization coverage and disease incidence. [2] Safety of vaccines, therefore, must be excellent to make it acceptable, since it usually has a deferred individual benefit, but immediate adverse drug reactions (ADRs). Vaccine pharmacovigilance is defined as the science and activities relating to the detection, assessment, understanding, prevention, and communication of adverse events following immunization, or of any other vaccine- or immunization-related issues. The WHO defines an adverse event following immunization (AEFI) as "a medical incident that takes place after an immunization causes concern, and is believed to be caused by the immunization." The goal of vaccine pharmacovigilance is the early detection and timely response to adverse events following immunization, in order to minimize negative effects to the health of individuals and lessen the potential negative impact on immunization of population.

Although vaccines are considered to be medicines with anti-infective activity that work by immunological action and administered for prophylaxis, pharmacovigilance for vaccines should be different from other drugs because of the following reasons.

  1. Information to be captured is complex and different from other drugs.

    Vaccines are complex biological products, which may include multiple antigens, live organisms, adjuvants, and preservatives. ADRs may be due to administration of live wild viruses e.g. lymphocyte meningitis after anti-mumps vaccine or may be non-specific, related to a component different from the antigen (aluminum hydroxide involved in the "macrophagic myofasciitis," allergic reactions to neomycin, latex, egg, or gelatin). [3] So, each component has unique safety implications, which require different information to capture as compared to other drugs. In a vaccination campaign, the vaccine is administered to a large population over a short period of time, which may result in administration error and hence has to be dealt with differently.
  2. Different modes of causality assessment

    There are some issues, which make evaluation of vaccines different from other drugs. Local or immediate adverse reactions, which occur due to administrative error and attenuated virus, can be attributed with a degree of confidence but delayed events are difficult to correlate. They have immunological considerations in addition to pharmacological action and take a long time to respond. [4] Criteria commonly used to determine causality such as resolution of the event following treatment discontinuation and the result of re-challenge cannot be used to assess causality of an event occurring after vaccination. [5]
  3. Reporters and reporting chain

    Vaccines are a part of national health plan and physicians involved in primary health care conduct the immunization en masse. So, reporter and reporting chain are different, especially in developing countries where physicians involved in primary health care are not exposed to technology (internet, etc) and pharmacovigilance sensitization.

    Although pharmacovigilance of vaccines is important, yet it is given much less attention. There are no different systems and regulatory guidelines in most of the countries for this activity. Lot of research is going on for vaccine development in infectious diseases e.g. HIV, malaria, H1N1, etc that have a high patient load. For the last two decades, pharmacovigilance has been gaining an increasing attention. It is now, high time that vaccines also receive their due attention.


 
  References Top

1.Ronald DM, Elizabeth BA. The basis of Pharmacovigilance introduction. In: Ronald DM, Elizabeth BA, editors. Pharmacovigilance. 2 nd ed., 2 nd ed. Great Britain: John Wiley Sons Inc; 2007. p. 1-3.  Back to cited text no. 1      
2.Concept paper for a guideline on the conduct of pharmacovigilance for vaccines. European Medicines Agency. 2005. Available from: http://www.emea.europa.eu/pdfs/human/phvwp/37200405en.pdf . [accessed on 2009 Dec 1].  Back to cited text no. 2      
3.Autret-Leca E, Bensouda-Grimaldi L, Jonville-Bιra AP, Beau-Salinas F. Pharmacovigilance of vaccines. Arch Pediatr 2006;13:175-80.  Back to cited text no. 3      
4.Clajus C, Spiegel J, Brφcker V, Chatzikyrkou C, Kielstein JT. Minimal change nephrotic syndrome in an 82 year old patient following a tetanus-diphteria-poliomyelitis-vaccination. BMC Nephrol 2009;10:21.  Back to cited text no. 4      
5.WHO. Adverse Events Following Immunization (AEFI): Causality Assessment. World Health Organization. Available from: http://whqlibdoc.who.int/aide-memoire/a87773_eng.pdf. [accessed on 2009 Dec 14].  Back to cited text no. 5      



This article has been cited by
1 Pharmacovigilance: A Worldwide Master Key for Drug Safety Monitoring: Some Additional
C. Patel
Journal of Young Pharmacists. 2011; 3(2): 168
[Pubmed]
2 Pharmacovigilance: A worldwide master key for drug safety monitoring: Some additional information
Patel, C.
Journal of Young Pharmacists. 2011; 3(2): 168-169
[Pubmed]



 

Top
Print this article  Email this article

    

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Medknow